Impact of Essential Medicines List inclusion on rituximab utilisation in MS and NMOSD patients: A retrospective study

Key Points

• Rituximab utilization in patients increased significantly after inclusion on the essential medicines list.
• The retrospective analysis showed a notable rise of approximately 30% in rituximab use among targeted populations.
• Data was collected and analyzed from a medical registry spanning several treatment centers over three years.
• This analysis highlights the potential impact of policy changes on access to vital therapies, needing further exploration.